Sarah Sammons, MD
Medical Oncology · Boston, MANPI 1215203013
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,858 of the $100,911 with a category attached, or 83.1%. It is spread thinly across 16 manufacturers, the largest accounting for just 18.9%. 2025 is the largest year on record at $34,930, more than ten times the $101 reported in 2019.
Across 97 payments — averaging $1040.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$19K
- Daiichi Sankyo Company LTD$15K
- Astrazeneca UK Limited$13K
- Daiichi Sankyo Inc.$12K
- Lilly USA, LLC$9K
- Stemline Therapeutics Inc.$7K
- plus $26K from 10 others
Across 33 payments — averaging $48,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$886K
- Pfizer$240K
- Seagen Inc.$197K
- Eli Lilly$172K
- E.r. Squibb & Sons, L.L.C.$52K
- AbbVie$41K
- plus $19K from 3 others
What the payments were for
- Consulting fees$83,85883%
- Speaking & faculty fees$5,2735%
- Grants$3500%
- Travel & lodging$7,9568%
- Food & beverage$3,4193%
- Education$550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 21 | $19,092 |
| Daiichi Sankyo Company LTD | 7 | $15,001 |
| Astrazeneca UK Limited | 4 | $12,732 |
| Daiichi Sankyo Inc. | 14 | $11,847 |
| Lilly USA, LLC | 2 | $8,800 |
| Stemline Therapeutics Inc. | 9 | $6,982 |
| Eli Lilly | 11 | $6,505 |
| Gilead | 7 | $5,238 |
| Pfizer | 8 | $5,031 |
| Seagen Inc. | 4 | $4,468 |
| Novartis | 2 | $2,470 |
| Foundation Medicine, Inc. | 1 | $1,500 |
| Genentech USA, Inc. | 1 | $825 |
| Biontech SE | 3 | $203 |
| Roche Diagnostics Corporation | 2 | $186 |
| Puma Biotechnology, Inc. | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$100,911 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 48 | $926 |
| Tamoxifen Citrate | 15 | $393 |
| Anastrozole | 15 | $364 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Boston
- George DemetriBoston$1.6M
- Keith FlahertyBoston$932K
- Alicia MorgansBoston$690K
- Pasi Antero JanneBoston$458K
- Robert HaddadBoston$451K
- Irene GhobrialBoston$431K
- Joaquin Bellmunt MolinsBoston$415K
- Jeremy AbramsonBoston$334K
- Justin GainorBoston$324K
- Narjust FlorezBoston$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.